Navigation Links
EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
Date:2/18/2008

Out-Licensing Enhances EUSA's Strategic Focus on Late-Stage and Marketed

Products

DOYLESTOWN, Pennsylvania and OXFORD, England, February 18 /PRNewswire/ -- EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has out-licensed the exclusive world-wide rights to its preclinical-stage human anti-interleukin-6 antibody to GlaxoSmithKline (GSK) for a consideration of up to $44 million, comprising an upfront fee and development milestones, plus royalties on future sales. As part of the agreement EUSA will pay approximately 50% of the overall consideration to its development partner for the antibody, Vaccinex Inc. GSK will fund and conduct all future development, production and commercialization of the product.

Interleukin-6 is a pro-inflammatory cytokine and B-cell growth factor and acts as a resistance factor to standard chemotherapy. EUSA's product, OP-R003, is the first fully human anti-interleukin-6 antibody, with target indications in oncology and inflammatory diseases. OP-R003 is derived from a first generation murine antibody, elsilimomab, which has achieved promising clinical results as a lymphoma therapy. As a fully human antibody, OP-R003 has the potential to offer improved tolerability and a superior safety profile.

EUSA acquired OP-R003 as part of the company's 2007 acquisition of OPi SA. OPi had previously entered a collaboration with Vaccinex, a specialist antibody discovery and development company, to optimize and develop OP-R003 as a therapy for rheumatoid arthritis and lymphoma.

"The out-licensing of this early-stage antibody is another strategic milestone for EUSA, as we continue to focus our business on marketed and late-stage products in the oncology, pain control and critical care areas," said Bryan Morton, Chief Executive of EUSA Pharma.

Commenting on the acquisition, Brian McVe
'/>"/>

SOURCE EUSA Pharma Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... August 20, 2014 LunaDress, a popular ... cocktail dresses for ladies, is now providing a discount ... dresses . The company’s cheap white prom outfits are ... backless, and A-line outfits. , There are over ... product category, and the special offer is valid until ...
(Date:8/19/2014)... Los Angeles, CA (PRWEB) August 19, 2014 ... is an online training course designed to provide users ... businesses using proven email marketing techniques and strategies. The ... has created a buzz of excitement throughout the internet ... caught the attention of HonestyFirstReviews.com's Tiffany Hendricks prompting an ...
(Date:8/19/2014)... HealthDay Reporter TUESDAY, Aug. 19, ... infant has long been linked to development of asthma and ... risk may persist into the teen years. The study, ... underscores the dangers of parental smoking, experts say. ... a child,s risk of developing allergic disease even up to ...
(Date:8/19/2014)... Following the completion of a $16 million rooms renovation ... proud to debut the highly anticipated final phase of its ... of all public spaces to match the fresh look and ... dining experience at 1823 Kitchen and Bar and an innovative ... of 1823 Kitchen and Bar, Grand Hyatt Tampa Bay has ...
(Date:8/19/2014)... Program has selected three geriatric social work ... development and mentorship for projects that will improve ... for all older adults. , The 2014 Hartford/VA ... among veterans, transitions from VA nursing facilities back ... older veterans. The Hartford/VA Geriatric Scholars Program provides ...
Breaking Medicine News(10 mins):Health News:Popular Supplier LunaDress Providing an Exclusive Assortment of White Prom Dresses at a Discount of Up to 67% 2Health News:Anik Singal’s “Inbox Blueprint” Review Released By HonestyFirstReviews.com 2Health News:For Kids, Risks of Parental Smoking Persist Long-Term, Study Finds 2Health News:For Kids, Risks of Parental Smoking Persist Long-Term, Study Finds 3Health News:Grand Hyatt Tampa Bay Hotel Unveils the Finishing Touches of Its $20 Million Makeover 2
... Oct. 4 The following is a,statement regarding Microsoft,s ... information online:, It is encouraging that companies like ... health record (PHR) products and systems,that people can use ... companies will follow suit. Having ready access to your ...
... Orr, fired for managing diabetes at work but ... Thursday before House Judiciary,Subcommittee about his experience, ... today reiterated its strong support for the ADA,Restoration ... the landmark,1990 Americans with Disabilities Act. On Thursday, ...
... ACTON, Mass., Oct. 4 Psychemedics Corporation,(AMEX: ... joined the company,as Vice President, Controller. Jennifer ... financial,reporting activities, as well as the financial analysis ... Jennifer will,report directly to the Chairman and CEO. ...
... Connector, provides patients with virtual diabetes health- ... management ... Association today unveiled a new web-based diabetes tool that,makes it ... -- to,share and organize important health information to improve their ...
... BOSTON, Oct. 4 Diet.com has joined ... of the newly launched Microsoft,HealthVault consumer health ... which currently include,Diet.com Calorie/Meal Tracker, Diet.com Weight ... incorporated into HealthVault. The trackers will,enable users ...
... Oct. 4 Genta,Incorporated (Nasdaq: GNTA ) announced ... Raymond P. Warrell, Jr., will provide an,update of corporate ... 10th at 2:15 pm PDT. The conference will be ... The presentation will be webcast and accessible at the ...
Cached Medicine News:Health News:Statement Regarding Microsoft's Announcement of New Services to Help People Store Their Health Information Online 2Health News:American Diabetes Association Urges Congress to Pass ADA Restoration Act, Help End Employment Discrimination Against Americans with Diabetes 2Health News:American Diabetes Association Urges Congress to Pass ADA Restoration Act, Help End Employment Discrimination Against Americans with Diabetes 3Health News:Jennifer Chmieleski Joins Psychemedics Corporation as Top Financial Officer 2Health News:New Diabetes Tool Available on American Diabetes Association Web Site 2Health News:New Diabetes Tool Available on American Diabetes Association Web Site 3Health News:New Diabetes Tool Available on American Diabetes Association Web Site 4Health News:Diet.com Enters Strategic Collaboration To Support Microsoft HealthVault 2Health News:Genta to Present at Bio Investor Forum 2007 Conference 2Health News:Genta to Present at Bio Investor Forum 2007 Conference 3
(Date:8/19/2014)... , Aug. 19, 2014 Research and ... Products - Global Strategic Business Report" report to their ... for Anti-Adhesion Products in US$ Thousands by the following three ... Procedures. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ...
(Date:8/18/2014)... and HERZLIYA-PITUACH, Israel , Aug. ... OMX First North Premier, Stockholm : "IMNP"), ... that its application to list its common stock on the ... Market, a unit of the NASDAQ OMX Group. IMMUNE,s common ... Market at the opening of trading on August 21, 2014 ...
(Date:8/18/2014)... 2014 Reportlinker.com announces that a new market ... Russia Sinuscopes Market Outlook to 2020 ... Market Outlook to 2020 Summary ... 2020", provides key market data on the Russia Sinuscopes ... dollars, volume (in units) and average prices (in US ...
Breaking Medicine Technology:Global Anti-Adhesion Products - Strategic Business Report 2014 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 3Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 4Russia Sinuscopes Market Outlook to 2020 2Russia Sinuscopes Market Outlook to 2020 3Russia Sinuscopes Market Outlook to 2020 4
... , SCOTTSDALE, Ariz. , Jan. 22 Matrixx Initiatives, ... financial results for the fiscal 2010 third quarter, ended December 31, ... January 25, 2010 . An earnings conference call will be held the ... AM ET . , To access the teleconference, please call (888) 452-4006 ...
... ... Called Ampyra, to Improve Walking for People With All Types of ... The U.S. Food and Drug Administration has approved the ... Therapeutics) for its ability to improve walking speed in people with ...
Cached Medicine Technology:Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2010 Financial Results 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 4Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 5Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 6
... doubled Nd:YAG laser is mounted on Haag ... selected between 0.2 and 2.0 mJ. The ... and 700 microns. Knobs for laser energy ... on the laser head. The laser system ...
... Tango ophthalmic laser system provides two lasers ... and a photodisruptor for posterior capsulotomy and ... Nd:YAG producing pulsed 532 nm light. The ... nm. The appropriate laser can be easily ...
... Glaucoma Laser System features a patented technique ... glaucoma. It selectively targets pigmented cells and ... Selecta II is equipped with a Q-switch ... light, which induces the same cell replacement ...
Thin and smooth jaws, designed to enter trough 3 mm incision, cross action....
Medicine Products: